Belgium-based iTeos Therapeutics SA has regained rights to an early-stage cancer drug from Pfizer Inc which was being investigated in a Phase 1 trial as a potential single agent for treating patients with malignant gliomas.
A Phase 2 study of a new antibody treatment for Alzheimer’s disease has failed to meet its primary endpoint using an adaptive trial design that was intended to show efficacy at 12 months. Biogen Inc and Eisai Co Ltd said the blinded study will continue until the second half of 2018.
Pending regulatory approval, a first clinical trial of a gene edited treatment for patients with beta-thalassemia, an inherited blood disorder, will start in Europe in early 2018. The therapy has been developed by CrisprTherapeutics AG and Vertex Pharmaceuticals Inc.
OSE Immunotherapeutics SA is set to resume recruitment into a Phase 3 trial of patients with non-small cell lung cancer (NSCLC) following a pause in June to enable investigators to have more time to assess the effect of the treatment which is a neoantigen therapy called Tedopi.
Avelumab, a checkpoint antibody that is the mainstay of Merck KGaA’s immuno-oncology portfolio, has failed to show superior overall survival in patients with metastatic gastric cancer compared with chemotherapy. The data is from a Phase 3 trial called Javelin Gastric 300.
An immuno-oncology combination that had initially produced an objective response in a Phase 1/2 trial of patients with head and neck cancer, failed to show benefit in an extended patient population, Innate Pharma SA announced on 22 November.
A new small molecule drug intended to treat cystic fibrosis patients with the F508del gene mutation has been well tolerated in patients in a Phase 2 study, paving the way for its use as part of a triple therapy, Galapagos NV announced on 19 November.
Roche has reported positive Phase 3 results for two different antibody therapeutics putting it in a leadership position for treating both non-small cell lung cancer and haemophilia A. The cancer trial was significant because it showed the benefits of using a checkpoint inhibitor as part of a triple therapy.
Finland-based Faron Pharmaceuticals Oy is proposing to raise up to £10 million, before expenses, in a private share placement to support the late-stage development and commercialisation of its product for acute respiratory distress syndrome Traumakine.
New longer-term data from a Phase 3 trial of the drug guselkumab for plaque psoriasis has shown that patients achieved consistent rates of skin clearance following treatment at both 52 and 100 weeks, according to the developer Janssen Research & Development LLC.